Pregnancy and Lactation Studies
ENROLLING PREGNANCY AND LACTATION STUDIES
BELIMUMAB (BENLYSTA™) PREGNANCY REGISTRY
If you are pregnant and have been given belimumab (BENLYSTA™) within the four months prior to becoming pregnant and/or during pregnancy, you are eligible to participate in this global registry. The pregnant woman or one of her health care providers may contact the registry at:
- Toll-free phone number (U.S.): +1 877 681 6296
- Toll-free worldwide access fax number: +1 855 269 6182
- Email address: [email protected]
- Website: http://pregnancyregistry.gsk.com/belimumab.html
BEMPEDOIC acid PREGNANCY suRVEILLANCE PROGRAM
If you are pregnant and have taken Nexletol® (bempedoic acid) or Nexlizet® (bempedoic acid/ezetimibe) at any time during pregnancy, you are eligible to participate in this study. The pregnant woman or one of her health care providers may contact the registry at:
- Toll-free phone number (U.S.): +1 833 377 7633 (Option 5)
- Email address: [email protected]
The CHERISH study
CHERISH is a clinical research study that will measure certolizumab pegol (Cimzia®) plasma levels in the blood over the course of pregnancy and after delivery. By participating in the study, you may help provide new information that may benefit pregnant women who have an inflammatory disease in the future. The information learned from this study may lead toward a better understanding how Cimzia® works during pregnancy.
- Toll-free phone number (U.S.): +1 877 302 2822
- Email address: [email protected]
- Website: https://thecherishstudy.com/us/en/screener
- Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04163016?term=UP0085&draw=2&rank=1
GLOW PREGNANCY REGISTRY
If you have been exposed to SKYRIZI®(risankizumab-rzaa) or related medication during pregnancy or within 5 months (20 weeks) prior to becoming pregnant, you may be eligible to participate in this U.S. registry. Pregnant women and their healthcare providers may contact the registry at:
- Toll-free phone number (North America): +1 877 302 2161
- Toll-free worldwide access fax number: +1 877 896 0927
- Email address: [email protected]
HEPLISAV-B® (Hepatitis B Vaccine [Recombinant], Adjuvanted) Pregnancy Registry
Pregnant women who have been vaccinated with HEPLISAV-B® (Hepatitis B Vaccine [Recombinant], Adjuvanted) within 28 days prior to conception or at any time during the pregnancy are eligible to participate in this U.S. registry. They may contact the registry at:
- Toll-free phone number (U.S.): +1 844 443 7734
- Toll-free fax number (U.S.): +1 877 202 3940
- Email address: [email protected]
- Website: https://heplisavbpregnancyregistry.com
The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
If you are a pregnant person diagnosed with migraine and have taken Nurtec® ODT (rimegepant) or other migraine medications during pregnancy you may qualify to participate. Pregnant people (residing in the US) and their healthcare providers may contact the registry at:
- Toll-free phone number (U.S.): +1 877 366 0324
- Email address: [email protected]
- Website: https://nurtecpregnancyregistry.com
T.A.P.P. (Take Action to Prevent Pregnancy) Pregnancy Monitoring Program for Acitretin
If you think you’ve become pregnant while taking Acitretin or within three years of stopping, contact the program at:
- Toll-free phone number (U.S.): +1 855 850 2138
- Toll-free fax number (U.S.): +1 855 850 2137
- Website: http://www.tevagenerics.com/acitretin
WAKIX® (pitolisant) Pregnancy Registry
If you have become pregnant while taking WAKIX® (pitolisant) or if you have taken WAKIX® at any time during your pregnancy, you are encouraged to enroll in this registry. The pregnant woman or one of her health care providers may contact the registry at:
- Toll-free phone number (U.S.): + 1 877 302 2813
- Toll-free fax number (U.S.): + 1 877 777 5622
- Email address: [email protected]
- Website: www.wakixpregnancyregistry.com
CLOSED PREGNANCY AND LACTATION STUDIES
BEXSERO® Pregnancy Registry
An observational study of the use and safety of BEXSERO® in pregnant women and their offspring.
https://clinicaltrials.gov/ct2/show/NCT02640677?term=Bexsero+Pregnancy+Registry&rank=1
CRADLE
A multicenter postmarketing study to evaluate breast milk transfer in lactating mothers receiving treatment for rheumatoid arthritis, Crohn’s disease, psoriatic arthritis or ankylosing spondylitis.
https://clinicaltrials.gov/ct2/show/NCT02154425?term=CRADLE&rank=3
CRIB
A multicenter postmarketing study to evaluate placental transfer in women receiving treatment for rheumatoid arthritis, Crohn’s disease, psoriatic arthritis or ankylosing spondylitis.
https://clinicaltrials.gov/ct2/show/NCT02019602?term=CRIB&rank=4
MENVEO® Vaccine Pregnancy Registry
An observational study of the use and safety of MENVEO® in pregnant women and their offspring.
https://www.clinicaltrials.gov/ct2/show/NCT02223637?term=Menveo+pregnancy+registry&rank=1
Oseltamivir Safety in Pregnancy
European-based, retrospective, observational, database study assessing the safety of oseltamivir exposure in pregnant women and their offspring.
Email address: [email protected]
Vedolizumab (Entyvio®) Lactation Study
A multicenter postmarketing study to evaluate breast milk transfer in women receiving vedolizumab (Entyvio®) for ulcerative colitis or Crohn’s disease.
https://www.clinicaltrials.gov/ct2/show/NCT02559713?term=Vedolizumab+%28Entyvio%C2%AE%29+Lactation+Study&rank=1
Xolair® Pregnancy Registry
An observational study of the use and safety of Xolair® (Omalizumab) during pregnancy (EXPECT).
https://clinicaltrials.gov/ct2/show/NCT00373061?term=EXPECT&rank=10
Zanamivir (Relenza inhalation powder) Safety in Pregnancy
European-based, retrospective, observational, database study assessing the safety of zanamivir (Relenza inhalation powder) exposure in pregnant women and their offspring.
Email address:
[email protected]